Blog
RSS FeedPosted by Michael Wonder on 09 Aug 2022
Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council report
9 August 2022 - Health technology assessment has been growing in use over the past 40 years, especially in its impact ...
Posted by Michael Wonder on 04 Aug 2022
The patient voice – the value of patient-reported outcomes in HTA
4 August 2022 - The patient’s voice is increasingly important in securing access for therapies in markets and demonstrating how ...
Posted by Michael Wonder on 03 Aug 2022
Pralsetinib for treating advanced RET fusion positive non-small-cell lung cancer
3 August 2022 - NICE has published evidence-based recommendations on the use of pralsetinib (Gavreto) for the treatment of adults ...
Posted by Michael Wonder on 28 Jul 2022
Novartis’ Beovu recommended by NICE
28 July 2022 - Patients set to benefit from new treatment for sight-threatening eye condition ...
Posted by Michael Wonder on 27 Jul 2022
Duvelisib for patients with chronic lymphocytic leukaemia
27 July 2022 - NICE has published a final technology appraisal for duvelisib for the treatment of patients with relapsed ...
Posted by Michael Wonder on 23 Jul 2022
European Union regulation of health technology assessment: what is required for it to succeed?
22 July 2022 - After considerable discussion and debate, the European Commission proposal for the regulation of health technology assessment was ...
Posted by Michael Wonder on 20 Jul 2022
The big squeeze?
20 July 2022 - With NHS England highlighting savings of £1.2 billion on medicines in three years coming from both ...
Posted by Michael Wonder on 18 Jul 2022
Velmanase alfa for the treatment of alfa mannosidosis
15 July 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using velmanase alfa ...
Posted by Michael Wonder on 15 Jul 2022
UK lags behind EU in authorising new medicines after Brexit
14 July 2022 - Experts attribute shortfall to small size of British market now it is regulated separately and complexity of ...
Posted by Michael Wonder on 14 Jul 2022
Breakthrough treatment to boost life chances for hundreds of people with respiratory cancer
14 July 2022 - The first new mesothelioma treatment to be approved in nearly 15 years will be made available ...
Posted by Michael Wonder on 14 Jul 2022
Thousands of patients to benefit as NHS marks 100th fast tracked cancer drug
14 July 2022 - Thousands of people a year with advanced breast cancer will benefit from a life extending drug ...
Posted by Michael Wonder on 14 Jul 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease
13 July 2022 - NICE has published evidence-based recommendations on the use of roxadustat (Evrenzo) for the treatment of adults ...
Posted by Michael Wonder on 14 Jul 2022
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
14 July 2022 - An agreement with the companies on the price of two breast cancer treatments, Piqray and Trodelvy, has ...
Posted by Michael Wonder on 13 Jul 2022
NICE terminates appraisal of belimumab for new indication
13 July 2022 - You guessed it, the sponsor decided not to lodge an evidence submission. ...
Posted by Michael Wonder on 13 Jul 2022
NICE issues final guidance on the use of risankizumab for psoriatic arthritis
13 July 2022 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of adults ...